both will likely get FDA approvals very soon based on anecdotal evidence.
The FDA doesn't approve on anecdotal evidence. I haven't been paying attention to where HGEN is in it's latest trial, CYDY will be releasing trial data shortly.
Neither CYDY nor HGEN will be able to fully/solely supply the COVID treatment global demand to calm the cytokine storm.
true
Let's just hope neither company is bought out at current bargain basement prices given the potential revenue from the COVID crisis.
I don't know about Durrant but Pourhassan will dismiss anything that doesn't take into account future potential.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.